摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Methoxy-2,4,5,6-tetrafluor-toluol | 68395-58-4

中文名称
——
中文别名
——
英文名称
3-Methoxy-2,4,5,6-tetrafluor-toluol
英文别名
1,2,3,5-Tetrafluoro-4-methoxy-6-methylbenzene
3-Methoxy-2,4,5,6-tetrafluor-toluol化学式
CAS
68395-58-4
化学式
C8H6F4O
mdl
——
分子量
194.129
InChiKey
VMVQFZOJFKSXGN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUNDS AND METHODS FOR PURIFYING PEPTIDES PRODUCED BY SOLID PHASE PEPTIDE SYNTHESIS
    申请人:Aucagne Vincent
    公开号:US20120226019A1
    公开(公告)日:2012-09-06
    The invention relates to compounds which can be used for purifying peptides produced by solid phase peptide synthesis. In addition, the invention relates to methods for purifying peptides produced by solid phase peptide synthesis using the compounds according to the invention.
    本发明涉及可用于纯化固相肽合成产物的化合物。此外,本发明还涉及使用本发明中的化合物纯化固相肽合成产物的方法。
  • NITRIC OXIDE DONOR COMPOUNDS
    申请人:Almirante Nicoletta
    公开号:US20100099729A1
    公开(公告)日:2010-04-22
    The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolismsdysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.
    本发明涉及一种一氧化氮供体化合物及其在治疗心血管疾病、炎症、疼痛、发热、胃肠道疾病、眼科疾病、肝脏疾病、肾脏疾病、呼吸系统疾病、免疫系统疾病、骨代谢功能障碍、中枢神经系统和周围神经系统疾病、性功能障碍、感染性疾病、抑制血小板聚集和血小板粘附、治疗由异常细胞增殖引起的病理性状况以及血管疾病方面的应用。该发明还涉及包含本发明中至少一种一氧化氮释放化合物的组合物,以及包含本发明中至少一种一氧化氮释放化合物和至少一种治疗剂的组合物。
  • USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN
    申请人:Impagnatiello Francesco
    公开号:US20100179192A1
    公开(公告)日:2010-07-15
    The present invention relates to nitrooxyderivative of antioxidant compounds of formula (I) and pharmaceutically acceptable salts or stereoisomers thereof for the treatment of chronic pain, in particular chronic neuropathic pain. The invention also describes composition comprising a nitrooxyderivative of a antioxidant compound of formula (I) and an analgesic drugs.
    本发明涉及公式(I)的抗氧化剂化合物的硝基氧衍生物及其药学上可接受的盐或立体异构体,用于治疗慢性疼痛,特别是慢性神经病性疼痛。本发明还描述了一种包含公式(I)的抗氧化剂化合物的硝基氧衍生物和镇痛药物的组合物。
  • SUBSTITUTED 2-(9H-PURIN-9-YL) ACETIC ACID ANALOGUES AS INHIBITORS OF STAT3
    申请人:Turkson James
    公开号:US20130172340A1
    公开(公告)日:2013-07-04
    In one aspect, the invention relates to substituted purine analogs, derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    在某个方面,本发明涉及取代嘌呤类似物、其衍生物和相关化合物,这些化合物可用作STAT蛋白活性的抑制剂;制备这些化合物的合成方法;包含这些化合物的药物组合物;以及使用这些化合物和组合物治疗与STAT蛋白活性功能障碍相关的细胞无控制增殖疾病的方法。本摘要旨在作为搜索特定技术领域的扫描工具,不旨在限制本发明。
  • [EN] NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN<br/>[FR] INHIBITEURS DE CÉTONE NON HYDRATÉS DE NAV1.7 POUR LE TRAITEMENT DE LA DOULEUR
    申请人:SITEONE THERAPEUTICS INC
    公开号:WO2022036297A1
    公开(公告)日:2022-02-17
    Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified, non-hydrated ketone saxitoxins.
    本文提供化合物、包含该化合物的药物组合物、制备该化合物的方法,以及使用该化合物和组合物治疗与电压门控钠通道功能相关的疾病的方法,其中该化合物是经过11,13改性的非水合酮类腥毒素。
查看更多